NCT03510689

Genetics and Heart Health After Cancer Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 79 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease

Conditions

• Breast Cancer
• Hereditary Breast/Ovarian Cancer (brca1, Brca2)
• Heart Diseases
• Drug-Induced Cardiomyopathy

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	echocardiography	Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
OTHER	Cardiopulmonary Exercise Testing	A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
OTHER	Blood Collection	We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.

Timeline

• Start date: 2017-12-05
• Primary completion: 2022-05-31
• Completion: 2022-05-31
• First posted: 2018-04-27
• Last updated: 2024-10-16

Locations

1 site across 1 country: United States